地西他滨、阿扎胞苷治疗高危骨髓增生异常综合征的疗效分析  

Analysis on Efficacy of Decitabine and Azacitidine in Treatment of High-Risk Myelodysplastic Syndrome

作　　者：唐琳洁[1] 罗泉芳[1] 朱世为[1] 王薇[1] Tang Lin-jie;Luo Quan-fang;Zhu Shi-wei;Wang Wei(Department of Hematology,Nanxishan Hospital in Guangxi Zhuang Autonomous Region,Guilin 541800,Guangxi Zhuang Autonomous Region,China)

机构地区：[1]广西壮族自治区南溪山医院血液内科,广西桂林541800

出　　处：《中国社区医师》2022年第29期43-45,共3页Chinese Community Doctors

基　　金：广西壮族自治区卫生健康委员会科研课题(Z20201033)。

摘　　要：目的:分析高危骨髓增生异常综合征(MDS)患者采用地西他滨、阿扎胞苷治疗的临床疗效。方法:选取2020年3月-2021年12月广西壮族自治区南溪山医院收治的高危MDS患者28例,随机分为两组,各14例。对照组采用阿扎胞苷治疗,观察组采用地西他滨治疗。比较两组患者治疗效果、不良反应发生率、生存质量、血常规指标情况。结果:观察组治疗后总有效率为71.4%,对照组为57.1%,两组差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。观察组生存质量评分与对照组比较均明显升高,差异有统计学意义(P<0.05);随访1年后,观察组生存率为85.7%(12/14),明显高于对照组的64.3%(9/14),两组差异有统计学意义(P<0.05)。观察组血红蛋白、白细胞计数、中性粒细胞计数均明显优于对照组,差异有统计学意义(P<0.05)。结论:与阿扎胞苷相比,采用地西他滨治疗高危MDS的效果更加理想,但不良反应发生率较高,因此临床在进行药物选择时,需根据患者病情慎重考虑,保障患者的生存质量。Objective:To analyze the clinical efficacy of decitabine and azacitidine in the treatment of patients with high-risk myelodysplastic syndrome(MDS).Methods:From March 2020 to December 2021,28 patients with high-risk MDS who were admitted to Nanxishan Hospital in Guangxi Zhuang Autonomous Region were selected and randomly divided into two groups,with 14 patients in each group.The control group was treated with azacitidine,and the observation group was treated with decitabine.The treatment effect,incidence of adverse reactions,quality of life and blood routine indicators of the two groups were compared.Results:The total effective rate after treatment in the observation group was 71.4%and that in the control group was 57.1%,and the difference between the two groups was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Compared with the control group,the quality of life score of the observation group was significantly increased,and the difference was statistically significant(P<0.05).After one year of follow-up,the survival rate of the observation group was 85.7%(12/14),which was significantly higher than 64.3%(9/14)of the control group,and the difference between the two groups was statistically significant(P<0.05).The hemoglobin,white blood cell count and neutrophil count of the observation group were significantly better than those in the control group,and the difference was statistically significant(P<0.05).Conclusion:Compared with azacitidine,the effect of decitabine in the treatment of high-risk MDS is more ideal,but the incidence of adverse reactions is higher.In the drug selection for clinical treatment,the patient's condition should be carefully considered,and the quality of life of the patient should be guaranteed.

关 键 词：高危骨髓增生异常综合征 地西他滨 阿扎胞苷 

分 类 号：R551.3[医药卫生—血液循环系统疾病]